Pulmonary emphysema is a risk factor for radiation pneumonitis in NSCLC patients with squamous cell carcinoma after thoracic radiation therapy

Ziyang Zhou1, Xiao Song2, Ailu Wu1, Hui Liu2, Hongyu Wu2, Qiongya Wu1, Yu Liu3, Yefei Li1, Yong Cai1 & Shixiong Liang1

Pulmonary emphysema (PE) has been demonstrated to have a high prevalence in patients with locally advanced non-small cell lung cancer (NSCLC). A total of 153 patients with locally advanced NSCLC were enrolled in this study to investigate the association between PE and radiation pneumonitis (RP) after definitive thoracic radiation therapy (TRT). The incidence of RP in Grade 2, 3 and 5 were 11.1%, 9.8% and 0.7%, respectively. Univariate analysis revealed that age, PE, forced vital capacity (FVC), arterial partial pressure of oxygen (PO2) and mean lung dose (MLD) were significantly associated with the risk of Grade ≥2 or Grade ≥3 RP in patients with squamous cell carcinoma (SCC, P < 0.05). Logistic analysis demonstrated that PE was an independent risk factor of RP in SCC (P < 0.05). Receiver operating characteristics (ROC) analysis revealed that the combination of age, PE, FVC, PO2 and MLD had a higher value to predict RP in SCC (AUC = 0.856 in Grade ≥2 RP and 0.882 in Grade ≥3 RP, respectively). Kaplan-Meier analysis revealed that the more severe the PE, the higher the incidence of RP in SCC. Our results revealed that PE was a high risk factor for locally advanced NSCLC patients followed definitive TRT, especially for SCC patients.

Non-small cell lung cancer (NSCLC) is the most common cancer, and is the most common cause of cancer-related mortality globally. NSCLC accounts for 85% of cases with lung cancer, which includes two major histologic subtypes, squamous cell carcinoma (SCC) and adenocarcinoma (ADE); and these subtypes are the distinction that carries significant clinical and therapeutic implications. Thoracic radiation therapy (TRT) is considered the standard treatment for patients with unresectable locally advanced NSCLC. However, normal lung tissue is sensitive to radiation, and radiation pneumonitis (RP) is the most important dose-limiting complication of TRT, which is irreversible and fatal in some cases. The clinical manifestation of RP is usually mild dry cough, fever, or mild dyspnea, and the severe RP could cause extensive pulmonary fibrosis, which may lead to chronic dyspnea and even death. The incidence of moderate and severe RP ranges from 10–20%. RP is the major side effect of TRT, which can impact on the clinical course of patients. Clinical factors and dosimetric factors are two common complications influencing the occurrence of RP. Clinical factors comprise performance status, tumor location, smoking history and concurrent chemotherapy, and dosimetric factors include V5 (volume of total lung receiving ≥5 Gy), V20 (volume of total lung receiving ≥20 Gy), mean lung dose (MLD), irradiated lung volume, total dose and fractionation schedule. These factors have been used to predict the occurrence of RP and have been reported in previous studies.

Chronic obstructive pulmonary disease (COPD) is a common disease characterized by the continuous deterioration of lung function, and has an increased prevalence in China, and present a high prevalence of 40–70% in lung cancer patients. Some recent investigations determined the correlation between COPD and RP, which
causes oncologists to regard COPD as a limitation for TRT in patients of lung cancer due to poor pulmonary function. Pulmonary emphysema (PE) is a crucial subtype of COPD, which is defined pathologically as a group of diseases that demonstrate anatomical alterations in the lung characterized by the enlargement of air spaces distal to the terminal bronchiole and accompanied by destructive changes of the alveolar walls. However, it remains unclear whether the presence of PE is associated with the incidence of RP or severity RP in patients with locally advanced NSCLC. The aim of this study is to evaluate the impact of PE on the incidence of RP in patients with locally advanced NSCLC after definitive TRT.

Materials and Methods

Patient demographics. A total of 153 consecutive patients, who were diagnosed as locally advanced NSCLC by histology and radiology and treated with TRT in Shanghai Pulmonary Hospital from January 2014 to January 2015, were enrolled in this study. Recruitment criteria were as follows: (1) patients who had a Karnofsky performance status (KPS) score >70, and could endure a definitive TRT at a total dose of 58–66 Gy (1.8–2.5 Gy/ fraction/day); (2) patients who received TRT with concurrent/sequential chemoradiotherapy; (3) patients with thoracic CT images taken prior and during TRT, which are available for evaluation; (4) patients with RP who were followed up for <6 months. The prospective evaluation, which included age, gender, smoking history, histology, stage and PE, were assessed through thoracic CT scans. All patients were staged as IIIA or IIIB based on the classification of tumor/node/metastasis (TNM) stages (International Union Against Cancer TNM classification, 7th edition), and were thereby considered inoperable. Patients with severe PE or poor lung function were considered not suitable for concurrent chemoradiotherapy, and the older patients were reluctant to choose this treatment mode due to poor endurance. All methods mentioned in the protocol were carried out in accordance with institutional guidelines and were approved by the Ethical Review Committee of Shanghai Pulmonary Hospital, Tongji University. Informed consent was obtained from all patients.

Radiotherapy. All patients received a planning CT scan and were immobilized in the supine position with their arms raised in a customized alpha-cracle mold. The simulation CT images were taken in 5-mm increments over the region of interest. Gross tumor volume (GTV) consisted of all known sites of the disease and considered large if it was ≥100 cc. Treatment planning was performed with the ADAC pinnacle treatment planning system. Treatments were delivered with 6 MV photons by 3D-conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) on a linear accelerator (Clinac 21EX, Varian Medical Systems, USA) or a Siemens Artiste (Oncology Care Systems, Siemens Medical Solutions, Concord, CA, USA) digital linear accelerator with a multi-leaf collimator. A planning target volume (PTV) was established to add margins for GTV and for beam position error, which was defined by the radiation oncologist. The planning goal was to deliver the prescription dose to at least 95% of the PTV, while meeting normal tissue constraints. The median total dose was 60 Gy (range: 58–66 Gy), and the fraction dose was 1.8–2.5 Gy (median 2.0 Gy). Patients who underwent stereotactic body radiation therapy (SBRT) were excluded from this study. Dose parameters V5, V10, V15, V20 and V25 were obtained as the percentages of the pulmonary volume irradiated to >5, >10, >15, >20 and >25 Gy, respectively. At the same time, mean lung dose (MLD) was calculated. The complete dose-volume histogram (DVH) data were available for all patients.

Chemotherapy. All patients received chemotherapy. Among these patients, 22 patients were concurrently given chemotherapy, and 131 patients were sequentially given chemotherapy. Among these 131 patients, 123 patients received chemotherapy first and eight patients received TRT first. Although there was no specific chemotherapy protocol, the former usually consisted of GP (gemcitabine and cisplatin; 69 patients, 45.1%), NP (vinorelbine and cisplatin; 20 patients, 13.1%), or TP (toxal and cisplatin; 15 patients, 9.8%). Two courses of consolidation chemotherapy were administered in 69 patients (45.1%).

Evaluation of PE and RP in CT images. PE was assessed according to the low-attenuation areas (LAAs) on CT scans taken prior to treatment, and was classified into five grades based on Satoh K’s criteria: no LAAs was classified as Grade 0, sparse and scattered small LAAs up to 5 mm in diameter was classified as Grade 1, adjacent LAAs up to 10 mm in diameter was classified as Grade 2, adjacent or indistinguishable LAAs >10 mm in diameter was classified as Grade 3, and almost no present normal lung parenchyma was classified as Grade 4. The PE grades according to our CT scans are presented in Fig. 1. No patient suffered Grade 4 PE in the present study. According to the Common Terminology Criteria for Adverse Events 4.0, RP was diagnosed through clinical symptoms and the radiographic changes on the CT scans of patients. These patients were graded as follows: Grade 0, no symptom or radiographic change; Grade 1, asymptomatic and radiographic changes only; Grade 2, symptomatic but did not interfering with the daily life of the patient; Grade 3, symptomatic, interfered with the daily life of the patient, and O2 was needed; Grade 4, life-threatening and ventilator support indicated; Grade 5, death. RP was graded by several experienced radiation oncologists at our institution to ensure the veracity of the grading. The RP grades based on the CT scans are shown in Fig. 2.

Follow-up. A CT scan prior to treatment was necessary for all patients, which was basically planed at the first 1–2 months after TRT. Patients were follow-up weekly up to the end of TRT and every 1–3 months thereafter, in order to evaluate the curative effect and determine adverse events. The follow-up period lasted for more than one year, as the patient’s physical status remained stable. The endpoint was the incidence of Grade ≥2 RP.

Statistical analysis. The association between RP and clinical factors were analyzed using Person Chi-square test or Continuity Correction test. The relationships between PE score and RP Grade were assessed using Spearman’s correlation test. Receiver operating characteristic (ROC) curves and Kaplan-Meier methods were carried out to analyze possible predictors and the cumulative incidence rates of Grade ≥2 and Grade ≥3 RP.
respectively. Multivariate logistic regression analyses were performed to evaluate the data for the association between clinical factors and DVH parameters with RP. Statistical analyses were performed using SPSS software 13.0. A $P$-value $< 0.05$ was considered significant.

Figure 1. Pulmonary emphysema (PE) in computed tomographic (CT) images: (a) Grade 0, no low-attenuation areas (LAAs); (b) Grade 1, sparse and scattered small LAAs up to 5 mm in diameter; (c) Grade 2, adjacent LAAs up to 10 mm in diameter; (d) Grade 3, adjacent or indistinguishable LAAs $> 10$ mm in diameter.

Figure 2. Radiation pneumonitis (RP) in computed tomographic (CT) images: (a) Grade 1, (b) Grade 2, (c) Grade 3, and (d) Grades 4–5.
factor with the association of Grade ≥ 2 RP (OR ≥ 1.985, \( P < 0.012 \)) and older age (\( P = 0.022 \)), respectively. Gender, primary tumor location, pathology, smoking history, forced expiratory volume in 1 second (FEV1)/FVC\%, arterial partial pressure of oxygen (PO\(_2\)), chemotherapy modality (sequential or concurrent), as well as dosimetric parameters including V5, V20 and MLD, were not related to the risk of developing Grade ≥ 2 RP (all \( P > 0.05 \), Table 2). In order to perform further investigation, these patients were divided into two groups for a subgroup analysis based on the different pathologies. Results revealed that there was no risk factor for patients with non-squamous cell carcinoma patients to suffer from Grade ≥ 2 RP, but for patients with SCC, age (\( P = 0.014 \)), FEV1/FVC\% (\( P = 0.007 \)) and PO\(_2\) (\( P = 0.02 \)) presented significant association with the development of Grade ≥ 2 RP.

The univariate analysis results for risk factors associated with Grade ≥ 3 RP are presented in Table 3. The results showed that higher PE Grade (\( P = 0.006 \)) and older age (\( P = 0.009 \)) were significantly associated with the development of Grade ≥ 3 RP in NSCLC. Furthermore, the stratified analysis revealed that V5 was the only factor related to Grade ≥ 3 RP (\( P = 0.01 \)) in non-squamous cell carcinoma patients, while in patients with SCC, older age (\( P = 0.032 \)), higher PE grade (\( P = 0.007 \)) and higher mean lung dose (MLD, \( P = 0.037 \)) presented significant results in Grade ≥ 3 RP. The results of unconditional logistic analysis showed that PE was the major factor with the association of Grade ≥ 2 RP (OR = 1.985, \( P = 0.01 \)) and Grade ≥ 3 RP (OR = 2.275, \( P = 0.02 \)) in NSCLC. Subgroup analysis showed that PE was the independent factor with the development of Grade ≥ 2 RP (OR = 3.304, \( P = 0.002 \)) and Grade ≥ 3 RP (OR = 2.718, \( P = 0.031 \)) in patients with SCC (Table 4).

Receiver operating characteristics (ROC) analysis. The multivariate analysis revealed that PE was the only independent risk factor for the incidence of RP in patients with SCC, and the relationship between PE and RP was analyzed using Spearman’s analysis. Results revealed that PE Grade was positively correlated with RP grade (\( \rho = 0.249, P = 0.002 \)). In addition, the ROC curve revealed that the area under the curve (AUC) of PE in NSCLC was 0.647 (\( P = 0.01 \)) in Grade ≥ 2 RP and 0.715 (\( P < 0.001 \)) in Grade ≥ 3 RP; and with the combination of RP and V5, the area under the curve was 0.825 (\( P < 0.001 \)) in Grade ≥ 3 RP.

Table 1. Demographics of patients. aOther types of pathology included adenosquamous carcinoma and some NSCLC with a non-clear diagnosis. bSequence 1, patients who received chemotherapy first. cSequence 2, patients who received radiation therapy first. dRP, radiation pneumonitis.

| Characteristic          | n  |
|-------------------------|----|
| Gender                  |    |
| Male                    | 140 (91.5%) |
| Female                  | 13 (8.5%) |
| Age (years)             |    |
| Range                   | 40–85 |
| Median                  | 63  |
| Pathology               |    |
| Adenocarcinoma          | 28 (18.3%) |
| Squamous cell carcinoma | 93 (60.8%) |
| Others\(^a\)            | 32 (20.9%) |
| Stage                   |    |
| IIIA                    | 55 (35.9%) |
| IIIB                    | 98 (64.1%) |
| Smoking history         |    |
| Yes                     | 94 (61.4%) |
| No                      | 59 (38.6) |
| Tumor location          |    |
| Upper lobe              | 87 (56.9%) |
| Middle lobe             | 29 (18.9%) |
| Lower lobe              | 37 (24.2%) |
| Chemotherapy            |    |
| Concurrent              | 22 (14.4%) |
| Sequence 1\(^b\)        | 123 (80.4%) |
| Sequence 2\(^c\)        | 8 (5.2%) |
| RP Grade\(^d\)          |    |
| 0–1                     | 120 (78.4%) |
| 2                       | 17 (11.1%) |
| 3                       | 15 (9.8%) |
| 5                       | 1 (0.7%) |

Results

Incidence of radiation pneumonitis and pulmonary emphysema. 140 male and 13 female patients were enrolled in this study. The characteristics of these patients are summarized in Table 1. The median follow-up was 10 months for all patients. The incidence of Grade ≥ 2 RP was 21.6% (33 patients), including 1 patient (0.7%) with fatal RP (Grade 5) and 15 patients (9.8%) with Grade 3 RP. No patient suffered from Grade 4 RP. The occurrence of RP ranged from 1 to 11 months (4.1 ± 2.8 months) after the start of TRT. PE occurred in 68 patients, including 45 patients (29.4%) in Grade 1, 22 patients (14.4%) in Grade 2, and 1 patient (0.7%) in Grade 3.
Table 2. Univariate analysis of possible risk factors associated with the development of Grade ≥2 RP. RP: radiation pneumonitis; G2, grade 2; G3, grade 3; PE, pulmonary emphysema; FEV1/FVC, forced expiratory volume in one second; FVC, forced vital capacity; PO2, arterial partial pressure of oxygen; PCO2, arterial partial pressure of carbon dioxide; V5, V20, the percentages of pulmonary volume irradiation exceeding 5 Gy, 20 Gy; MLD, mean lung dose. *Sequence 1, patients who received chemotherapy first. †Sequence 2, patients who received radiation therapy first. Significant differences are indicated in bold.

| Risk factors | Non-small cell lung cancer (n = 153) | Non-squamous cell carcinoma (n = 60) | Squamous cell carcinoma (n = 93) |
|--------------|--------------------------------------|-------------------------------------|---------------------------------|
|              | RP < G2 (%) | RP ≥ G2 (%) | P-value | RP < G2 (%) | RP ≥ G2 (%) | P-value | RP < G2 (%) | RP ≥ G2 (%) | P-value |
| Gender       | Male        | 110        | 30       | >0.999     | 38        | 11       | >0.999     | 72        | 19       | >0.999     |
|              | Female      | 10         | 3        | 8          | 3         | 2        | 8          | 0         |          |
| Age          | 62.19 ± 8.89 | 65.70 ± 9.58 | 0.050 | 63.26 ± 9.31 | 63.71 ± 10.29 | 0.613 | 61.53 ± 8.62 | 67.16 ± 9.02 | 0.014 |
| Tumor location | Upper    | 67         | 20       | 0.656      | 23        | 7        | 0.703      | 44        | 13       | 0.736      |
|              | Middle      | 22         | 7        | 9          | 4         | 13       | 3          |           |
|              | Lower       | 31         | 6        | 14         | 3         | 17       | 3          |           |
| Smoking history | Yes      | 75         | 19       | 0.607      | 25        | 6        | 0.451      | 50        | 13       | 0.943      |
|              | No          | 45         | 14       | 21         | 8         | 24       | 6          |           |
| chemotherapy | Concurrent  | 20         | 2        | 0.248      | 9         | 0        | 0.059      | 11        | 2        | 0.424      |
|              | Sequence 1  | 94         | 29       | 0.342      | 12        | 0        | 0.028      | 7        | 0        | 1.000      |
|              | Sequence 2  | 6          | 2        | 3          | 2         | 3        | 0          |           |
| PE Grade     | 0           | 73         | 12       | 0.012      | 29        | 8        | 0.162      | 44        | 4        | <0.001     |
|              | ≥2          | 13         | 10       | 5          | 0        | 0        | 8          | 10       |          |
| FEV1/FVC%    | ≥70         | 56         | 15       | 0.902      | 22        | 8        | 0.542      | 34        | 7        | 0.476      |
|              | <70         | 64         | 18       | 24         | 6        | 40       | 12         |           |
| FVC          | ≥2.8        | 67         | 11       | 0.022      | 22        | 6        | 0.744      | 45        | 5        | 0.007      |
|              | <2.8        | 53         | 22       | 24         | 8        | 29       | 14         |           |
| PO2          | 84.13 ± 11.85 | 81.42 ± 9.07 | 0.225 | 81.43 ± 13.40 | 84.00 ± 7.92 | 0.085 | 85.81 ± 10.54 | 79.53 ± 9.58 | 0.020 |
| PCO2         | 37.49 ± 4.09 | 36.93 ± 4.51 | 0.497 | 37.33 ± 4.03 | 36.87 ± 4.67 | 0.813 | 37.59 ± 4.15 | 36.98 ± 4.52 | 0.573 |
| V5           | 49.14 ± 7.64 | 50.52 ± 7.51 | 0.260 | 49.28 ± 7.44 | 50.36 ± 8.46 | 0.680 | 49.03 ± 7.71 | 50.63 ± 6.96 | 0.425 |
| V20          | 22.16 ± 3.96 | 23.55 ± 3.96 | 0.077 | 21.93 ± 3.99 | 23.50 ± 4.36 | 0.565 | 22.30 ± 3.97 | 23.58 ± 3.78 | 0.268 |
| MLD          | 11.88 ± 2.61 | 12.69 ± 2.67 | 0.118 | 11.96 ± 2.60 | 12.47 ± 3.21 | 0.210 | 11.83 ± 2.63 | 12.85 ± 2.27 | 0.125 |

Discussion
RP remains a major problem that may result in considerable morbidity and limit the dose of radiation treatment in NSCLC patients. Grade ≥2 RP was considered as a symptomatic RP that requires intervention treatment, and Grade ≥3 RP is regarded as severe RP that could lead to poor prognosis. As progress has been made in understanding the underlying mechanism of RP, more work is needed to develop a safe and effective means of preventing and treating this condition. This prospective study aimed to evaluate the incidence rate and risk factors of RP after TRT for lung cancer in a large single institution series. Dosimetric factors such as V20 and MLD are considered to be highly correlated with the incidence of RP in NSCLC patients. Grade ≥2 RP in SCC patients with PE Grade 0, PE Grade 1 and PE Grade ≥2 were 12 (14.1%), 11 (24.4%) and 10 (43.5%), respectively, while the events of Grade ≥2 RP in NSCLC patients with PE Grade 0, PE Grade 1 and PE Grade ≥2 were 3 (3.5%), 8 (17.8%) and 5 (21.7%), respectively. The incidence of Grade ≥2 RP in SCC patients with PE Grade 0, PE Grade 1 and PE Grade ≥2 were 4 (8.3%), 5 (18.5%) and 10 (55.6%), respectively; and the incidence of Grade ≥3 RP in SCC patients with PE Grade 0, PE Grade 1 and PE Grade ≥2 were 1 (2.1%), 4 (14.8%) and 5 (27.8%), respectively.
### Table 3. Univariate analysis of possible risk factors associated with the development of Grade ≥3 RP. RP: radiation pneumonitis; G2, grade 2; G3, grade 3; PE, pulmonary emphysema; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; PO2, arterial partial pressure of oxygen; PCO2, arterial partial pressure of carbon dioxide; V5, V20, the percentages of pulmonary volume irradiation exceeding 5 Gy, 20 Gy; MLD, mean lung dose. aSequence 1, patients who received chemotherapy first. bSequence 2, patients who received radiation therapy first. Significant differences are indicated in bold.

| Risk factors | Non-small cell lung cancer (n = 153) | Non-squamous cell carcinoma (n = 60) | Squamous cell carcinoma (n = 93) |
|--------------|--------------------------------------|-------------------------------------|--------------------------------|
|              | RP < G3 (%) | RP ≥ G3 (%) | P-value | RP < G3 (%) | RP ≥ G3 (%) | P-value | RP < G3 (%) | RP ≥ G3 (%) | P-value |
| Gender       | Male       | 125        | 15      | >0.999     | 44         | 5       | >0.999     | 81         | 10      | >0.999 |
|              | Female     | 12         | 1       |            | 10         | 1       |            | 2          | 0       |        |
| Age          |            | 62.29 ± 8.90 | 68.56 ± 9.46 | 0.009 | 62.76 ± 9.52 | 68.83 ± 7.36 | 0.307 | 61.99 ± 8.51 | 68.40 ± 10.91 | 0.032 |
| Tumor location | Upper | 77         | 10      | 0.847      | 27         | 3       | 0.692      | 50         | 7       | 0.765 |
|              | Middle     | 26         | 3       |            | 11         | 2       |            | 15         | 1       |        |
|              | Lower      | 34         | 3       |            | 16         | 1       |            | 18         | 2       |        |
| Smoking history | Yes | 84         | 10      | 0.927      | 28         | 3       | >0.999     | 56         | 7       | >0.999 |
|              | No         | 53         | 6       |            | 26         | 3       |            | 27         | 3       |        |
| Chemotherapy | Concurrent | 21         | 1       | 0.559      | 9          | 0       | 0.304      | 12         | 1       | 0.641 |
|              | Sequence 1 | 109        | 14      | 0.927      | 41         | 5       |            | 68         | 9       |        |
|              | Sequence 2 | 7          | 1       |            | 4          | 1       |            | 3          | 0       |        |
| PE Grade     | 0          | 82         | 3       | 0.006      | 35         | 2       | 0.112      | 47         | 1       | 0.007 |
|              | ≥2         | 18         | 5       |            | 5          | 0       |            | 13         | 5       |        |
| FEV1/FVC %   | ≥70        | 65         | 6       | 0.450      | 27         | 3       | >0.999     | 38         | 3       | 0.540 |
|              | <70        | 72         | 10      |            | 27         | 3       |            | 45         | 7       |        |
| FVC          | ≥2.8       | 72         | 6       | 0.254      | 25         | 3       | >0.999     | 47         | 3       | 0.208 |
|              | <2.8       | 65         | 10      | 0.29       | 9          | 3       |            | 36         | 7       |        |
| PO2          |            | 83.97 ± 11.71 | 79.94 ± 6.72 | 0.179 | 82.19 ± 12.86 | 80.67 ± 6.19 | 0.307 | 85.13 ± 10.81 | 79.50 ± 7.31 | 0.113 |
| PCO2         |            | 37.54 ± 4.27 | 35.98 ± 3.05 | 0.158 | 37.38 ± 4.26 | 35.82 ± 2.89 | 0.103 | 37.64 ± 4.30 | 36.07 ± 3.30 | 0.269 |
| V5           |            | 49.25 ± 7.75 | 51.06 ± 6.17 | 0.368 | 49.37 ± 8.02 | 51.00 ± 1.10 | 0.010 | 49.17 ± 7.62 | 51.10 ± 7.92 | 0.453 |
| V20          |            | 22.27 ± 3.98 | 24.06 ± 3.84 | 0.089 | 22.11 ± 4.12 | 24.00 ± 3.74 | 0.562 | 22.37 ± 3.91 | 24.10 ± 4.09 | 0.192 |
| MLD          |            | 11.93 ± 2.64 | 13.09 ± 2.39 | 0.098 | 12.07 ± 2.78 | 12.17 ± 2.49 | 0.882 | 11.85 ± 2.56 | 13.64 ± 2.27 | 0.037 |

### Table 4. Unconditional logistic analysis of possible risk factors associated with the development of RP. *P for the trend of grade 0, Grade 1 and Grade ≥2; RP, radiation pneumonitis; OR, odds ratio; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma; G2, Grade 2; G3, Grade 3; PE, pulmonary emphysema; FVC, forced vital capacity; PO2, arterial partial pressure of oxygen; MLD, mean lung dose. Significant differences are indicated in bold.

| Risk factors | NSCLC patients with RP ≥G2 | NSCLC patients with RP ≥G3 | SCC patients with RP ≥G2 | SCC patients with RP ≥G3 |
|--------------|---------------------------|---------------------------|--------------------------|--------------------------|
| Age          | 1.028 (0.980–1.079)       | 0.259                     | 1.078 (1.004–1.157)      | 0.037                    |
|              | 1.043 (0.972–1.120)       | 0.240                     | 1.058 (0.966–1.159)      | 0.221                    |
| PE Grade     | 1.985 (1.174–3.354)       | 0.010*                    | 2.275 (1.141–4.533)      | 0.002*                   |
|              | 3.304 (1.555–7.023)       | 0.002*                    | 2.718 (1.096–6.740)      | 0.031*                   |
| FVC          | 2.403 (0.960–6.017)       | 0.061                     | 1.131 (0.321–3.980)      | 0.848                    |
|              | 3.681 (0.974–13.914)      | 0.055                     | 2.049 (0.381–11.020)     | 0.403                    |
| PO2          | 1.002 (0.964–1.041)       | 0.928                     | 0.986 (0.936–1.039)      | 0.597                    |
|              | 0.951 (0.892–1.013)       | 0.119                     | 0.958 (0.884–1.038)      | 0.292                    |
| MLD          | 1.129 (0.962–1.326)       | 0.137                     | 1.192 (0.951–1.493)      | 0.128                    |
|              | 1.170 (0.925–1.481)       | 0.191                     | 1.336 (0.967–1.844)      | 0.079                    |

patients with SCC after TRT. Moreover, the combination of age, PE, FVC, PO2 and MLD had a higher value to predict the occurrence of RP.

Although the relationship between RP and COPD including PE has been investigated in recent years, it still remains controversial. Some researchers have pointed out that patients with COPD or PE have a higher risk of suffering from RP8,15, while other researchers reported that patients with severe COPD or PE had lower risk of suffering from RP followed by SBRT16,17. In addition, other researchers have shown that PE was irrelevant to the incidence of RP after TRT13,14. Our results revealed that PE was a risk factor related to RP, but this association only existed in NSCLC patients with SCC. This is a new finding for radiation oncologists, because few researches have focused on the risk of RP between different types of pathology in NSCLC. The main reasons considered are as follows: First, the majority of SCC have been considered to occur centrally and grow largely. Hence, the GTV capacity; PO2, arterial partial pressure of oxygen; MLD, mean lung dose. Significant differences are indicated in bold.

patients with SCC after TRT. Moreover, the combination of age, PE, FVC, PO2 and MLD had a higher value to predict the occurrence of RP.
level of reactive oxygen species (ROS)\textsuperscript{18}. Those factors could positively enhance lung injury. Finally, local and systemic chronic inflammation, which was the main characteristic of COPD and PE, might cause chronic mitogenesis and increase the likelihood of DNA damage\textsuperscript{19}. This mechanism was considered to be a trigger of RP\textsuperscript{20}.

The association between age and RP was also investigated in recent studies. Tsujino et al.\textsuperscript{14} reported that an age of $\geq 68$ was a risk factor in their model for predicting severe RP in a retrospectively study of 122 patients, who had a median age of 63 years old. A literature-based meta-analysis pooled 11 studies for age comparison, and concluded that older patients were more likely to increase RP risk\textsuperscript{21}. Some other studies revealed that age was not a significant risk factor associated with RP\textsuperscript{13, 16}. It is noteworthy that these studies commonly used the median age as the dichotomizing value, while the practice of dichotomizing continuous covariates was considered unnecessary for statistical analysis\textsuperscript{22}. Additionally, poor pulmonary function tests did not increase the risk of RP, as been reported in some investigations\textsuperscript{14, 16}. They suggested that TRT could also be a good treatment option for patients with NSCLC combined with COPD or PE. However, in a prospective study, Jeba et al.\textsuperscript{23} revealed that there was a universal fall in all pulmonary function parameters except for Diffusing Capacity for Carbon Monoxide (DLCO) in patients with RP. Hence, the main consideration on the adverse reaction of TRT in patients with COPD was not RP, but the worsening of lung function. Furthermore, no study has reported on whether age or pulmonary function factors could be a good predictor for RP in patients with SCC. Our data revealed an insignificant value in the correlation of RP and age or pulmonary function after the multivariate analysis. However, the combination of the five factors (age, PE, FVC, PO\textsubscript{2} and MLD) provided a higher accuracy to predict RP than PE only. Consequently, careful observation and management of RP should be provided after TRT in such patients with older age, higher grades of PE and severe pulmonary function.

There were some limitations in this study. Concurrent chemoradiotherapy is usually the standard treatment for patients with locally advanced NSCLC\textsuperscript{24}. However, cases that underwent concurrent chemoradiotherapy were less than the other studies in our data. After the statistics analysis, we found that there was no difference in RP rate, regardless of whether patients accepted concurrent chemoradiotherapy or not; and this coincided with the results of other investigations\textsuperscript{14, 16}. Nevertheless, concurrent chemoradiotherapy should be encouraged for patients with a good condition to endure the adverse reaction, in order to improve the local control of NSCLC. Another limitation is that the diagnosis of PE was evaluated through CT images, which lacks prospective data or physiological data to demonstrate the correlation of PE and RP. In addition, the number of patients with Grade $\geq 3$ PE was not enough to draw a definitive conclusion, which would reduce the statistical power of this study. Therefore, further prospective studies will be needed to assess our results.

**Figure 3.** Receiving operator characteristic (ROC) curve based on the sensitivity and specificity of pulmonary emphysema (PE) alone, and the combination of age, PE, forced vital capacity (FVC), arterial partial pressure of oxygen (PO\textsubscript{2}) and mean lung dose (MLD). (a) ROC curve of Grade $\geq 2$ RP in non-small cell lung cancer (NSCLC); (b) ROC curve of Grade $\geq 3$ RP in NSCLC; (c) ROC curve of Grade $\geq 2$ RP in squamous cell carcinoma (SCC); (d) ROC curve of Grade $\geq 3$ RP in SCC.
In summary, our study focused on the investigation of risk factors for the occurrence of RP in locally advanced NSCLC patients. It was revealed that age, PE, FVC, PO$_2$, and MLD were significantly associated with the incidence of RP. Further analysis revealed that PE was an independent risk factor for RP. The combination of age, PE, FVC, PO$_2$, and MLD had a higher value to predict the occurrence of RP in SCC, than in NSCLC. PE was a high risk factor for locally advanced NSCLC patients after definitive TRT, especially for SCC patients.

References
1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA: a cancer journal for clinicians 63, 11–30 (2013).
2. Mehta, V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. International journal of radiation oncology, biology, physics 63, 5–24 (2005).
3. Seppenwoolde, Y. & Lebesque, J. V. Partial irradiation of the lung. Seminars in radiation oncology 11, 247–258 (2001).
4. Rodrigues, G., Lock, M., D’Souza, D., Yu, E. & Van Dyk, J. Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer—a systematic review. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 71, 127–138 (2004).
5. Loganathan, R. S., Stover, D. E., Shi, W. & Venkatraman, E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest 129, 1305–1312 (2006).
6. Young, R. P. et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. The European respiratory journal 34, 380–386 (2009).
7. Kocak, Z. et al. Challenges in defining radiation pneumonitis in patients with lung cancer. International journal of radiation oncology, biology, physics 62, 653–638 (2005).
8. Rancati, T., Ceresoli, G. L., Gagliardi, G., Schipani, S. & Cattaneo, G. M. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 67, 275–283 (2003).
9. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. The American review of respiratory disease 136, 225–244 (1987).
10. Deterbeck, F. C., Boffa, D. J. & Tanoue, L. T. The new lung cancer staging system. Chest 136, 260–271 (2009).
11. Satoh, K. et al. CT assessment of subtypes of pulmonary emphysema in smokers. Chest 120, 725–729 (2001).
12. Kocak, Z. et al. Prospective assessment of dosimetric/physiologic-based models for predicting radiation pneumonitis. International journal of radiation oncology, biology, physics 67, 178–186 (2007).
13. Yamaguchi, S. et al. Radiotherapy for thoracic tumors: association between subclinical interstitial lung disease and fatal radiation pneumonitis. International journal of clinical oncology 20, 45–52 (2015).
14. Tsuji, K. et al. Combined analysis of V20, V5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 9, 983–990 (2014).
15. Kharofa, J. & Gore, E. Symptomatic radiation pneumonitis in elderly patients receiving thoracic irradiation. *Clinical lung cancer* **14**, 283–287 (2013).

16. Kimura, T. *et al.* Radiation pneumonitis in patients with lung and mediastinal tumours: a retrospective study of risk factors focused on pulmonary emphysema. *The British journal of radiology* **85**, 135–141 (2012).

17. Ishijima, M. *et al.* Patients with severe emphysema have a low risk of radiation pneumonitis following stereotactic body radiotherapy. *The British journal of radiology* **88**, 20140596 (2015).

18. Jaroenpool, J., Pattanapanyasat, K., Noomin, N. & Prachongsai, I. Increased Reactive Oxygen Species (ROS) as Aberrant Neutrophil Function among Healthy Smokers with High Cigarette Smoking Profile and Chronic Obstructive Pulmonary Disease Patients. *Asian Pacific journal of allergy and immunology / launched by the Allergy and Immunology Society of Thailand* (2016).

19. Lee, G., Walser, T. C. & Dubinett, S. M. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. *Current opinion in pulmonary medicine* **15**, 303–307 (2009).

20. Xue, J. *et al.* Gene-modified mesenchymal stem cells protect against radiation-induced lung injury. *Molecular therapy: the journal of the American Society of Gene Therapy* **21**, 456–465 (2013).

21. Vogelius, I. R. & Bentzen, S. M. A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. *Acta oncologica (Stockholm, Sweden)* **51**, 975–983 (2012).

22. Naggara, O. *et al.* Analysis by categorizing or dichotomizing continuous variables is inadvisable: an example from the natural history of unruptured aneurysms. *AJNR. American journal of neuroradiology* **32**, 437–440 (2011).

23. Jeba, J. *et al.* Radiation Pneumonitis After Conventional Radiotherapy For Breast Cancer: A Prospective Study. *Journal of clinical and diagnostic research: JCDR* **9**, Xc01–xc05 (2015).

24. Glatzer, M., Elicin, O., Ramella, S., Nestle, U. & Putora, P. M. Radio(chemo)therapy in locally advanced nonsmall cell lung cancer. *European respiratory review: an official journal of the European Respiratory Society* **25**, 65–70 (2016).

**Author Contributions**

Shixiong Liang and Yong Cai designed the research, interpreted and discussed the results; Ailu Wu, Hui Liu, Hongyu Wu, Qiongya Wu, Yu Liu and Yefei Li collected the data; Ziyang Zhou and Xiao Song analyzed the data, wrote the manuscript; Shixiong Liang reviewed the manuscript.

**Additional Information**

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017